The Government of Venezuela through the Ministry of Popular Power for Health (MPPS) registered the Sputnik V vaccine against the coronavirus, under the emergency use authorization procedure, as announced by the Russian Direct Investment Fund (RDIF). It should be noted that the country is conducting phase III biological trials.
“We welcome the decision of the Venezuelan Ministry of Health to approve the use of Sputnik V, a safe and effective vaccine to prevent the spread of the coronavirus. Sputnik V is now an important part of the national vaccine portfolios of several Latin American countries and we hope that in the coming weeks there will be more vaccine associations in the region, ”said Kirill Dmitriev, Director General of the Russian Direct Investment Fund .
Key advantages of Sputnik V
According to a press release, the following aspects were taken into account for the registration:
- Efficiency greater than 90%, with total protection against severe cases of covid-19.
- It uses two different vectors for the two injections in a vaccination course, providing longer-lasting immunity than vaccines that use the same delivery mechanism for both injections.
- The safety, efficacy, and absence of long-term negative effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
- There are no strong allergies caused by Sputnik V.
More than 1,5 million people vaccinated
The developers of Sputnik V are working in collaboration with AstraZeneca on a joint clinical trial to improve the efficacy of this laboratory's vaccine.
Sputnik V has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria and Palestine; while the European Union has already started the approval process. .
Supply of the vaccine will be facilitated by Russia's Direct Investment Fund's international partners in India, China, South Korea and other countries.